A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and quality of life in patients with genital psoriasis over 32 weeks.

Dec 10, 2025 · Rocatinlimab, administered subcutaneously, results in clinically meaningful improvements in patients with moderate-to-severe atopic dermatitis, with an acceptable safety …

Dec 17, 2025 · In a randomized clinical trial, vixarelimab demonstrates dose-dependent, long-term safety and efficacy in patients with prurigo nodularis.

Mar 28, 2025 · Viral infection, nasopharyngitis, and bacterial infection were the most common adverse events. Fitusiran labeling contains a boxed warning of both thrombotic events and …

Mar 7, 2025 · Patients with moderate to severe papulopustular rosacea have better outcomes with low-dose minocycline than with placebo and doxycycline, according to two randomized trials.

3 days ago · Step 5: Look for a benign cause (eg, nasopharyngitis or viral gastroenteritis). Step 6: If fever is “isolated,” consider listeriosis. Caution: “Even if a blood culture (the only possible ...

Mar 28, 2016 · Dr Myerson provides a brief review of the approved PCSK9 inhibitors alirocumab and evolocumab, current indications, and anticipated data.

May 22, 2025 · The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

Jul 23, 2024 · Topical delgocitinib was effective and well tolerated in patients with chronic hand eczema with no safety concerns.

Jul 30, 2025 · Pegcetacoplan has been approved for the treatment of C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis in patients aged 12 years …